Company:  SORRENTO THERAPEUTICS, IN ... (SRNE)
Form Type:  4
Filing Date:  4/21/2017 
CIK:  0000850261 
Address:  4955 DIRECTORS PLACE 
City, State, Zip:  SAN DIEGO, California 92121 
Telephone:  858-203-4100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$6.30  
Change: 
0.10 (1.61%)  
Trade Time: 
Apr 20  
Market Cap: 
$573.48M
Trade SRNE now with

© 2018  
Description of Business
Sorrento Therapeutics, Inc. (Nasdaq: SRNE), together with its subsidiaries (collectively, the "Company", "we", "us" and "our") is a clinical stage biotechnology company focused on delivering clinically meaningful therapies to patients and their families, globally. Our primary focus is to transform cancer into a treatable or chronically manageable disease. We also have programs assessing the use of our technologies and products in auto-immune, inflammatory and neurodegenerative diseases and pain indications with high unmet medical needs. At our core, we are an antibody-centric company and leverage our proprietary G-MAB(TM) library and targeted delivery modalities to generate the next generation of cancer therapeutics. Our validated fully human antibodies include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT and CD137 among others.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES